🚨 Everything is back in stock — all peptides available now 🚨

What are GLP-1 agonists?

Written and maintained by the AVERON Research Desk · Last reviewed September 2026

GLP-1 agonists are one of the most significant developments in modern medicine. They began as diabetes treatments and are now among the most widely used medicines for weight management in the world. This page explains what they are, how they work, and how the compounds in this class differ.

What GLP-1 is

GLP-1, glucagon-like peptide-1, is a hormone released by the gut after eating. It belongs to a group called incretins. Among its effects, it:

  • increases insulin release when blood sugar is high
  • reduces the release of glucagon, a hormone that raises blood sugar
  • slows the emptying of the stomach, so food stays there longer
  • acts on the brain to increase the feeling of fullness and reduce appetite

Natural GLP-1 is broken down by the body within minutes, which makes it useless as a medicine. A GLP-1 agonist is a molecule designed to activate the same receptor for far longer.

A short history

The first GLP-1 agonist, exenatide, was approved in the United States in 2005. It was based on a peptide discovered in the saliva of the Gila monster lizard. Liraglutide followed, approved for diabetes in 2010 and for weight management in 2014. Semaglutide, which lasts long enough to be given once weekly, was approved for diabetes in 2017 and for weight management in 2021.

Single, dual and triple agonists

The newest compounds act on more than one receptor.

TypeReceptorsExampleStatus
Single agonistGLP-1SemaglutideApproved
Dual agonistGIP, GLP-1TirzepatideApproved
Triple agonistGIP, GLP-1, glucagonRetatrutideIn phase 3 trials

Adding GIP, another incretin, and then glucagon, which increases energy expenditure, was intended to produce larger effects. Trial results so far are consistent with that.

What the trials show

TrialCompoundLengthAverage weight changePlacebo
STEP 1 (2021)Semaglutide68 weeks−14.9%−2.4%
SURMOUNT-1 (2022)Tirzepatide72 weeks−20.9% at highest dose−3.1%
Phase 2 (2023)Retatrutide48 weeks−24.2% at highest dose−2.1%

These trials differed in size, length and stage, so they cannot be compared directly. The only head-to-head trial, SURMOUNT-5, found tirzepatide produced more weight loss than semaglutide. See tirzepatide vs semaglutide.

Side effects across the class

The most common effects are gastrointestinal: nausea, diarrhoea, vomiting and constipation, usually most noticeable while doses are being increased. Listed risks include pancreatitis and gallbladder disease. Approved products in the class carry a warning about thyroid C-cell tumours based on findings in rodents.

What GLP-1 agonists do not do

  • They are not stimulants and do not "burn fat" directly. Their effect comes largely from reduced appetite and slower digestion.
  • Weight tends to return after they are stopped. In the extension of the STEP 1 trial, most of the weight lost was regained within a year of stopping.
  • Part of the weight lost is lean mass, not only fat.
  • Research-grade material is not the same as a registered, branded medicine.

In Indonesia

Semaglutide and tirzepatide are both registered with BPOM, Indonesia's food and drug authority. Retatrutide is not approved anywhere.

In sport

Semaglutide and tirzepatide are not prohibited; GLP-1 agonists are on WADA's Monitoring Program. Retatrutide, as a compound still in development, falls under WADA category S0 and is prohibited.

Frequently asked questions

It activates the GLP-1 receptor, increasing insulin release when blood sugar is high, slowing stomach emptying and reducing appetite.

Semaglutide acts on one receptor, tirzepatide on two, and retatrutide on three. Semaglutide and tirzepatide are approved; retatrutide is in trials.

In the trials that stopped treatment, most participants regained much of the weight they had lost.

Semaglutide and tirzepatide are registered with BPOM. Retatrutide is not approved anywhere.

Approved GLP-1 agonists are on WADA's Monitoring Program, not the Prohibited List. Retatrutide falls under category S0.

Doses mentioned on this page are the arms of published trials, given to describe their results. They are not guidance.

Sources

  1. Wilding JPH, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021;384:989–1002. Link
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022;387:205–216. Link
  3. Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 2023;389:514–526. Link
  4. Wilding JPH, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022;24:1553–1564. Link
  5. World Anti-Doping Agency. The Prohibited List and Monitoring Program. WADA. Link

Related pages

...